On March 26, 2024 ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, reported that it will participate at the 2024 Cell and Gene Meeting on the Med, to be held from April 9-11, 2024 in Rome, Italy (Press release, ImmPACT-Bio, MAR 26, 2024, View Source [SID1234641465]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio’s chief executive officer, will provide a company presentation on Tuesday, April 9, 2024 at 12:00 PM CET. Dr. Ramachandra will also participate in an individual presentation and panel discussion entitled, "Advances in Targeting Autoimmune Disease," on Wednesday, April 10, 2024 at 10:45 AM CET.

Virtual attendance is available which includes a livestream of ImmPACT Bio’s presentation and the ability to view all conference sessions on-demand. Please visit View Source for full information including registration.